First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
JP Morgan approaches.
But Tevimbra’s role looks shaky as adverse events loom.
Four months after yielding first-in-human data INCA33890 enters phase 3.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Mocertatug rezetecan is starting its first western pivotal trials.
